CRL - Charles River Laboratories International Stock Price, Fair Value and News

221.61USD-3.14 (-1.40%)Market Closed

Market Summary

USD221.61-3.14

Market Closed

-1.40%

CRL Alerts

Big fall in earnings (Y/Y)

CRL Stock Price

View Fullscreen

CRL RSI Chart

CRL Valuation

Market Cap

11.4B

Price/Earnings (Trailing)

26.02

Price/Sales (Trailing)

2.78

EV/EBITDA

13.09

Price/Free Cashflow

16.21

CRL Price/Sales (Trailing)

CRL Profitability

EBT Margin

15.15%

Return on Equity

12.04%

Return on Assets

5.38%

Free Cashflow Yield

6.17%

CRL Fundamentals

CRL Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

-1.73%

Rev. Growth (Qtr)

-0.19%

CRL Earnings

Earnings (TTM)

438.8M

Earnings Growth (Yr)

-34.72%

Earnings Growth (Qtr)

-64.01%

Breaking Down CRL Revenue

Last 7 days

-2.8%

Last 30 days

-3.7%

Last 90 days

-9.5%

Trailing 12 Months

11.2%

How does CRL drawdown profile look like?

CRL Financial Health

Current Ratio

1.75

Debt/Equity

0.73

Debt/Cashflow

0.26

CRL Investor Care

Shares Dilution (1Y)

0.64%

Diluted EPS (TTM)

8.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	4.1B	0	0	0
2023	4.1B	4.2B	4.2B	4.1B
2022	3.6B	3.7B	3.8B	4.0B
2021	3.0B	3.3B	3.4B	3.5B
2020	2.7B	2.7B	2.8B	2.9B
2019	2.4B	2.4B	2.5B	2.6B
2018	1.9B	2.0B	2.1B	2.3B
2017	1.8B	1.8B	1.8B	1.9B
2016	1.4B	1.5B	1.6B	1.7B
2015	1.3B	1.3B	1.3B	1.4B
2014	1.2B	1.2B	1.3B	1.3B
2013	1.1B	1.1B	1.2B	1.2B
2012	1.1B	1.1B	1.1B	1.1B
2011	1.1B	1.1B	1.1B	1.1B
2010	1.2B	1.1B	1.1B	1.1B
2009	0	1.3B	1.2B	1.2B
2008	0	0	0	1.3B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Charles River Laboratories International

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	pease flavia	sold (taxes)	-207,792	232	-893	corporate executive vp & cfo
Mar 08, 2024	knell michael gunnar	sold	-216,156	267	-808	csvp&chief accounting officer
Mar 04, 2024	knell michael gunnar	sold	-717,890	261	-2,750	csvp&chief accounting officer
Mar 01, 2024	parisotto shannon m	gifted	-	-	-412	cevp, disc & safety assessment
Feb 29, 2024	creamer victoria l	sold	-1,268,500	253	-5,000	evp & chief people officer
Feb 29, 2024	parisotto shannon m	sold	-959,545	253	-3,786	cevp, disc & safety assessment
Feb 22, 2024	barbo william d	sold	-1,006,420	248	-4,050	corporate executive vp & cco
Feb 16, 2024	foster james c	gifted	-	-	-4,000	chairman, president and ceo
Feb 15, 2024	girshick birgit	gifted	-	-	-424	corporate executive vp & coo
Feb 15, 2024	laplume joseph w	sold	-200,223	238	-838	evp, corp strategy & develop

Which funds bought or sold CRL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Wahed Invest LLC	added	14.75	64,159	267,699	0.06%
May 17, 2024	New Covenant Trust Company, N.A.	new	-	9,212	9,212	0.01%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-0.1	2,761,020	21,800,900	0.03%
May 16, 2024	JANE STREET GROUP, LLC	added	14.64	1,109,560	4,643,270	-%
May 16, 2024	Grandeur Peak Global Advisors, LLC	reduced	-14.35	-318,994	17,092,300	1.36%
May 16, 2024	Tidal Investments LLC	added	99.81	808,466	1,435,160	0.02%
May 16, 2024	Ancora Advisors LLC	reduced	-1.02	560,236	4,725,370	0.11%
May 16, 2024	Pineridge Advisors LLC	sold off	-100	-11,820	-	-%
May 16, 2024	2Xideas AG	reduced	-22.91	-1,518,350	11,522,400	1.41%
May 16, 2024	COMERICA BANK	added	5.59	824,169	4,745,290	0.02%

Are Funds Buying or Selling CRL?

Are funds buying CRL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CRL

No. of Funds

CRL Alerts

Big fall in earnings (Y/Y)

Unveiling Charles River Laboratories International's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.66%	5,980,236	SC 13G/A
Jan 24, 2024	blackrock inc.	10.1%	5,195,086	SC 13G/A
Jul 07, 2023	blackrock inc.	10.2%	5,218,752	SC 13G/A
Feb 09, 2023	vanguard group inc	11.71%	5,956,960	SC 13G/A
Jan 31, 2023	fmr llc	-	0	SC 13G/A
Jan 24, 2023	blackrock inc.	9.8%	4,981,145	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 09, 2022	vanguard group inc	11.63%	5,869,125	SC 13G/A
Jan 28, 2022	blackrock inc.	10.1%	5,080,026	SC 13G/A
Feb 10, 2021	vanguard group inc	10.11%	5,027,904	SC 13G/A

Recent SEC filings of Charles River Laboratories International

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading

Peers (Alternatives to Charles River Laboratories International)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Charles River Laboratories International News

Latest updates

Charles River Laboratories International Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.2%	1,012	1,013	1,027	1,060	1,029	1,100	989	973	914	905	896	915	825	791	743	683	707	691	668	658	605
S&GA Expenses	-5.5%	186	197	176	200	175	200	184	132	150	144	149	172	156	143	128	128	130	130	130	136	123
EBITDA Margin	1.3%	0.26*	0.26*	0.25*	0.25*	0.25*	0.25*	0.21*	0.22*	0.22*	0.23*	0.23*	0.24*	-	-	-	-	-	-	-	-	-
Interest Expenses	4.3%	35.00	34.00	34.00	35.00	34.00	35.00	11.00	4.00	9.00	12.00	16.00	16.00	30.00	33.00	19.00	19.00	15.00	24.00	6.00	21.00	10.00
Income Taxes	24.2%	25.00	20.00	25.00	29.00	27.00	56.00	25.00	33.00	16.00	24.00	18.00	38.00	2.00	28.00	33.00	16.00	5.00	25.00	-0.32	15.00	11.00
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	106	73.00	59.00	66.00
EBT Margin	0.4%	0.15*	0.15*	0.15*	0.15*	0.15*	0.16*	0.13*	0.13*	0.13*	0.14*	0.13*	0.14*	-	-	-	-	-	-	-	-	-
Net Income	-64.0%	67.00	187	87.00	97.00	103	187	96.00	109	93.00	138	103	88.00	62.00	143	103	67.00	51.00	80.00	73.00	44.00	55.00
Net Income Margin	-7.1%	0.11*	0.11*	0.11*	0.12*	0.12*	0.12*	0.12*	0.12*	0.12*	0.11*	0.12*	0.12*	-	-	-	-	-	-	-	-	-
Free Cashflow	-41.2%	130	221	205	148	109	235	133	149	103	229	175	187	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.5%	8,153	8,195	7,607	7,772	7,699	7,603	7,383	7,529	7,075	7,024	7,058	6,720	5,809	5,491	5,213	5,241	5,202	4,693	4,583	4,625	3,927
Current Assets	3.7%	1,668	1,609	1,444	1,505	1,448	1,439	1,415	1,393	1,333	1,274	1,379	1,268	1,423	1,201	1,140	1,235	1,208	1,021	972	1,010	866
Cash Equivalents	22.3%	339	277	157	200	202	234	196	207	242	246	213	223	465	233	243	402	372	240	165	201	126
Inventory	-5.0%	361	380	293	285	263	256	262	257	221	199	182	194	194	186	181	168	163	161	156	135	130
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,124	-	-	1,033	1,044	1,008	1,006	907
Goodwill	-0.8%	3,070	3,095	2,885	2,917	2,902	2,850	2,776	2,860	216	2,712	2,736	240	612	72.00	1,778	1,736	1,732	210	1,522	-	-
Liabilities	-1.9%	4,449	4,536	4,256	4,472	4,543	4,579	4,711	4,836	4,404	4,432	4,594	4,366	3,593	3,347	3,288	3,460	3,522	3,026	3,018	3,147	2,505
Current Liabilities	-9.5%	955	1,055	994	1,008	981	1,092	1,014	1,048	994	1,033	984	930	803	840	787	728	691	710	682	636	530
Long Term Debt	0.5%	2,660	2,647	2,514	2,678	2,744	2,708	2,937	2,997	2,676	2,664	2,893	2,727	2,202	1,930	1,968	2,207	2,327	1,850	1,883	2,040	1,541
Shareholder's Equity	1.4%	3,646	3,597	3,306	3,258	3,114	2,976	2,633	2,653	2,615	2,539	2,432	2,323	2,188	2,118	1,901	1,757	1,656	1,638	1,536	1,458	1,401
Retained Earnings	3.8%	1,960	1,887	1,720	1,633	1,536	1,433	1,280	1,183	1,074	981	879	775	687	625	501	399	331	280	214	141	97.00
Additional Paid-In Capital	1.8%	1,939	1,906	1,877	1,850	1,830	1,805	1,781	1,761	1,745	1,718	1,720	1,691	1,660	1,628	1,614	1,590	1,563	1,532	1,515	1,498	1,481
Shares Outstanding	0.3%	52.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	51.00	50.00	50.00	50.00	-	-	-	-	-	-	-	-	-
Minority Interest	6.0%	6.00	5.00	5.00	6.00	5.00	5.00	6.00	5.00	5.00	4.00	5.00	5.00	4.00	4.00	5.00	4.00	4.00	3.00	4.00	3.00	3.00
Float	-	-	-	-	10,687	-	-	-	11,392	-	-	-	18,339	-	-	-	8,333	-	-	-	6,797	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-41.2%	129,888	220,943	205,450	148,122	109,383	234,757	132,779	149,474	102,630	229,258	174,722	186,590	170,229	138,379	177,300	162,306	68,590	180,677	155,847	129,553	14,859
Share Based Compensation	-14.3%	16,738	19,521	22,797	16,270	13,460	22,069	21,999	14,930	14,619	19,185	22,023	17,077	13,189	15,368	16,870	13,143	10,960	13,842	14,025	16,505	12,899
Cashflow From Investing	64.0%	-85,792	-238,371	-79,557	-76,609	-168,618	44,383	-92,186	-462,114	-98,005	9,307	-355,050	-954,193	-137,996	-88,423	-70,810	-28,626	-413,685	-70,871	-61,393	-528,425	-20,813
Cashflow From Financing	-85.2%	18,346	123,568	-162,866	-71,464	25,241	-248,956	-51,594	271,436	-13,283	-218,972	178,895	517,955	194,720	-59,229	-268,639	-104,096	479,212	-39,044	-133,443	473,507	-69,083
Buy Backs	6627.3%	9,351	139	38.00	4,966	19,012	159	24.00	4,474	33,994	267	143	4,269	36,028	74.00	112	118	23,675	47.00	157	123	17,760

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CRL Income Statement

2024-03-30

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Total revenue	$ 1,011,560	$ 1,029,373
Costs and expenses:
Cost of revenue (excluding amortization of intangible assets)	666,717	651,719
Selling, general and administrative	186,291	174,846
Amortization of intangible assets	32,575	34,916
Operating income	125,977	167,892
Other income (expense):
Interest income	2,202	806
Interest expense	(35,001)	(34,380)
Other income (expense), net	5,833	(3,277)
Income before income taxes	99,011	131,041
Provision for income taxes	24,529	27,087
Net income	74,482	103,954
Less: Net income attributable to noncontrolling interests	1,522	823
Net income available to Charles River Laboratories International, Inc.	72,960	103,131
Preferred Stock Dividends and Other Adjustments [Abstract]
Net income available to Charles River Laboratories International, Inc.	72,960	103,131
Less: Adjustment of redeemable noncontrolling interest	401	0
Less: Incremental dividends attributable to noncontrolling interest holders	5,230	0
Net income available to Charles River Laboratories International, Inc. common shareholders	$ 67,329	$ 103,131
Net income attributable to common shareholders:
Basic (in dollars per share)	$ 1.31	$ 2.02
Diluted (in dollars per share)	$ 1.30	$ 2.01
Weighted-average number of common shares outstanding:
Basic (in shares)	51,437	51,097
Diluted (in shares)	51,842	51,428
Cost of services provided (excluding amortization of intangible assets)
Total revenue	$ 816,862	$ 857,366
Costs and expenses:
Cost of revenue (excluding amortization of intangible assets)	578,164	565,477
Cost of products sold (excluding amortization of intangible assets)
Total revenue	194,698	172,007
Costs and expenses:
Cost of revenue (excluding amortization of intangible assets)	$ 88,553	$ 86,242

CRL Balance Sheet

2024-03-30

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 30, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents	$ 327,039	$ 276,771
Trade receivables and contract assets, net of allowances for credit losses of $25,407 and $25,722, respectively	786,980	780,375
Inventories	361,281	380,259
Prepaid assets	93,834	87,879
Other current assets	99,054	83,378
Total current assets	1,668,188	1,608,662
Property, plant and equipment, net	1,618,708	1,639,741
Venture capital and strategic equity investments	243,543	243,811
Operating lease right-of-use assets, net	384,394	394,029
Goodwill	3,070,241	3,095,045
Intangible assets, net	827,638	864,051
Deferred tax assets	36,924	40,279
Other assets	303,147	309,383
Total assets	8,152,783	8,195,001
Current liabilities:
Accounts payable	129,682	168,937
Accrued compensation	189,606	213,290
Deferred revenue	256,383	241,820
Accrued liabilities	190,892	227,825
Other current liabilities	188,247	203,210
Total current liabilities	954,810	1,055,082
Long-term debt, net and finance leases	2,660,459	2,647,147
Operating lease right-of-use liabilities	418,054	419,234
Deferred tax liabilities	180,094	191,349
Other long-term liabilities	235,441	223,191
Total liabilities	4,448,858	4,536,003
Commitments and contingencies (Notes 2, 11, 13, and 15)
Redeemable noncontrolling interest	57,775	56,722
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 51,552 shares issued and 51,510 shares outstanding as of March 30, 2024, and 51,338 shares issued and outstanding as of December 30, 2023	515	513
Additional paid-in capital	1,939,413	1,905,578
Retained earnings	1,959,777	1,887,218
Treasury stock, at cost, 42 and zero shares, as of March 30, 2024 and December 30, 2023, respectively	(9,351)	0
Accumulated other comprehensive loss	(249,919)	(196,427)
Total Charles River Laboratories International, Inc. equity	3,640,435	3,596,882
Nonredeemable noncontrolling interests	5,715	5,394
Total equity	3,646,150	3,602,276
Total liabilities, noncontrolling interests and equity	$ 8,152,783	$ 8,195,001

About Charles River Laboratories International

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

CEO	Mr. James C. Foster J.D.
WEBSITE	criver.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	20000

Charles River Laboratories International Frequently Asked Questions

What is the ticker symbol for Charles River Laboratories International? What does CRL stand for in stocks?

CRL is the stock ticker symbol of Charles River Laboratories International. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Charles River Laboratories International (CRL)?

As of Fri May 17 2024, market cap of Charles River Laboratories International is 11.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers. The fair value of Charles River Laboratories International is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Charles River Laboratories International is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Charles River Laboratories International a good stock to buy?

The fair value guage provides a quick view whether CRL is over valued or under valued. Whether Charles River Laboratories International is cheap or expensive depends on the assumptions which impact Charles River Laboratories International's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRL.

What is Charles River Laboratories International's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CRL's PE ratio (Price to Earnings) is 26.02 and Price to Sales (PS) ratio is 2.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Charles River Laboratories International's stock?

In the past 10 years, Charles River Laboratories International has provided 0.154 (multiply by 100 for percentage) rate of return.